Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming ...

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

The director of the FDA's Center for Drug Evaluation and Research, Patrizia Cavazzoni, MD, will step down from the role Jan. 18, according to an Endpoints News report. Dr. Cavazzoni joined the FDA ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

“Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process,” said Patrizia Cavazzoni, M.D., director of the ...

Dr. Scott Manthei of the Nevada Ear and Sinus Institute has been advising patients against taking drugs like Sudafed for ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

Major pharmacy chains and a state regulatory agency said Friday that they’re continuing to work with the FDA on how to best ... of COVID-19,” said Dr. Patrizia Cavazzoni, director for the ...

As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, ...